Document

What is the importance of JINARC® RMP?

The JINARC® RMP aims to reduce the risk of severe and potentially fatal liver injury associated with the use of JINARC®.

This is done by:

  • Educating healthcare providers about:
    • The risks of using JINARC®.
    • The importance of baseline & periodic monitoring.
    • The need to counsel patients on the risks of using JINARC®.
  • Ensuring they follow the monitoring requirements.
  • Informing patients about the risks and monitoring requirements.
  • Additionally, all patients using JINARC® are enrolled in a JINARC® Patient Support Database to further support long-term safety of JINARC®.

How to become a certified prescriber of JINARC®?

  1. Review the educational materials on JINARC®

    2. ✓ Prescribing Information

    ▶ ◀

    ✓ Prescribing Guide

    ▶ ◀

  2. Pass the Jinarc® Risk Management Assessment. Once you fulfill the requirement, the JINARC® RMP will send the certification to your registered e-mail address.

    3. ▶ ◀

How do I enroll a patient in the JINARC® RMP?

  1. Counsel the patient on the risks and monitoring requirements using the Patient Guide.

    2. ▶ ◀

  2. Order and evaluate liver function test (LFT) before the first prescription.
  3. After reviewing patient’s LFT, inform the patient to contact JINARC® Patient Support Team.

Telefax: 02-7576-0257

GLOBE: 0917-300-6456 (w/ Viber)

SMART: 0999-886-9801 (w/ Viber)

Once a patient is on JINARC®, how often should I monitor them?

  1. Order and review liver laboratory tests (liver transaminases and total bilirubin) at specific time points after treatment initiation, as follows:
  2. Assess the patient's liver function and determine the appropriateness of continuing treatment.

How should I report liver adverse events?

  • To report adverse events, adverse drug reactions or patient safety concerns, healthcare providers must notify the OPPI-Pharmacovigilance and collect the following information:

Description of event

Patient information

Otsuka product involved e.g. Tolvaptan (JINARC®)

Primary reporter contact information

OPPI-Pharmacovigilance:

✓Email: oppi-pv@otsuka.com.ph

✓Mobile: +63999 8869 910

✓Phone: +632 8844 9266, +632 8888 6774

✓Fax: +632 8811 2279

Safety Information Reporting Guide ▶ ◀

Full prescribing information available from Tolvaptan (Jinarc®) Package insert
Full prescribing information available from Tolvaptan (Jinarc®) Package insert
Tolvaptan (Jinarc®) [Package Insert]. Tokushima, Japan; OPC; December. 2022.